Hyperimmune immunoglobulin for hospitalised patients with COVID-19 (ITAC): a double-blind, placebo-controlled, phase 3, randomised trial

BACKGROUND: Passive immunotherapy using hyperimmune intravenous immunoglobulin (hIVIG) to SARS-CoV-2, derived from recovered donors, is a potential rapidly available, specific therapy for an outbreak infection such as SARS-CoV-2. Findings from randomised clinical trials of hIVIG for the treatment of...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8797010/
https://www.ncbi.nlm.nih.gov/pubmed/35093205
http://dx.doi.org/10.1016/S0140-6736(22)00101-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8797010/
https://www.ncbi.nlm.nih.gov/pubmed/35093205
http://dx.doi.org/10.1016/S0140-6736(22)00101-5

Ejemplares similares